Atrial fibrillation at mid-term after bioprosthetic aortic valve replacement – implications for anti-thrombotic therapy.

@article{Tosello2014AtrialFA,
  title={Atrial fibrillation at mid-term after bioprosthetic aortic valve replacement – implications for anti-thrombotic therapy.},
  author={Francesco Tosello and Emmanuelle Florens and Thibault Caruba and Christine Lebeller and L{\'e}a Mimoun and Alberto Milan and Jean-Noel Fabiani and Pierre Boutouyrie and Philippe Menasch{\'e} and Agn{\`e}s Lillo-Le-Louet},
  journal={Circulation journal : official journal of the Japanese Circulation Society},
  year={2014},
  volume={79 1},
  pages={
          70-6
        }
}
BACKGROUND Little is known about mid-term (3-month) postoperative atrial fibrillation (MT-POAF) in patients treated with bioprosthetic aortic valve replacement (BAVR). The aim of this study was to describe the natural history, identify the predictors and investigate the potential consequences in terms of anti-thrombotic therapy. METHODS AND RESULTS During a longitudinal, prospective study, 219 patients were treated with BAVR early (7 days) and at mid-term postoperatively (30 and 90 days… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 40 REFERENCES

: Prevention and treatment of atrial fibrillation following cardiac surgery

RO Bonow, BA Carabello, +3 authors Freed
  • Can J Cardiol
  • 2011

Body mass index predicts new - onset atrial fibrillation after cardiac surgery

JP Mathew, ML Fontes, +3 authors CD Mazer
  • Eur J Cardiothorac Surg
  • 2011